Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.50 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9968921 | 1.00 | TDP1 (0.54) | TDP1L3MBTL1CYSLTR2CYSLTR1FAAH | |
| SCHEMBL2771953 | 1.00 | TDP1 (0.54) | TDP1L3MBTL1CYSLTR2CYSLTR1FAAH | |
| SCHEMBL204170 | 0.87 | CYSLTR2 (0.54) | TDP1L3MBTL1CYSLTR2CYSLTR1FAAH | |
| SCHEMBL202662 | 0.82 | PRSS1 (0.52) | CYSLTR2CYSLTR1SMPD1KMT2APDK2 | |
| SCHEMBL4666452 | 0.82 | CYSLTR2 (0.54) | TDP1L3MBTL1CYSLTR2CYSLTR1FAAH | |
| SCHEMBL4667397 | 0.81 | THRA (0.57) | TDP1L3MBTL1CYSLTR2CYSLTR1FAAH | |
| SCHEMBL8279022 | 0.79 | TSHR (0.57) | TDP1L3MBTL1CYSLTR2CYSLTR1FAAH | |
| SCHEMBL10054169 | 0.79 | L3MBTL1 (0.62) | TDP1L3MBTL1CYSLTR2CYSLTR1FAAH | |
| SCHEMBL2805503 | 0.79 | THRA (0.45) | TDP1L3MBTL1BRD4GAARAB9A | |
| SCHEMBL9968920 | 0.79 | THRA (0.45) | TDP1L3MBTL1BRD4GAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202865-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-20100240658-A1 | Oxadiazole Derivatives | MERCK SERONO SA (CH) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240658-A1 | Oxadiazole Derivatives | OXA1L, RO60, NQO2 | TDP1 1894/4885L3MBTL1 3352/4885CYSLTR2 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.